EI
ADVM

EAM Investors’s Adverum Biotechnologies ADVM Stock Holding History

EAM Investors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,980
Closed -$2.71M – 268
2020
Q2 		$2.71M Buy
12,980
+2,277
+21% +$403K 0.6% 37
2020
Q1 		$1.05M Buy
+10,703
New +$1.25M 0.32% 142
2019
Q3 		– Sell
-23,204
Closed -$2.76M – 232
2019
Q2 		$2.76M Buy
+23,204
New +$1.92M 0.67% 32
2015
Q2 		– Sell
-1,973
Closed -$800K – 314
2015
Q1 		$800K Sell
1,973
-421
-18% -$178K 0.09% 320
2014
Q4 		$1.29M Buy
+2,394
New +$923K 0.18% 244

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EAM Investors's ADVM Position: Q3 2020 in Review

EAM Investors sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 12,980 shares — an estimated $2.71M sold.

EAM Investors first reported a position in ADVM in Q4 2014 and held it in 5 quarters. The position peaked at $2.76M in Q2 2019. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • EAM Investors reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • EAM Investors sold 12,980 Adverum Biotechnologies shares in Q3 2020, an estimated $2.71M.
  • EAM Investors first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 5 quarters.
  • EAM Investors's Adverum Biotechnologies position peaked at $2.76M in Q2 2019.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.